bioAffinity Technologies, Inc. (BIAF) stock: key figures, P/E, revenue and dividend
Industrials · United States · ISIN US09076W3079
bioAffinity Technologies, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 6.16 m USD |
| Operating income | -10.57 m USD |
| EBIT | -14.84 m USD |
| Net income | -14.91 m USD |
| Diluted EPS – continuing operations | -8.66 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
More stocks
- Longeveron Inc. (LGVN)
- Aqua Metals, Inc. (AQMS)
- GOLD ROCK HOLDINGS, INC. (GRHI)
- DataMeds AI, Inc. (MEDS)
- Advanced Biomed Inc. (ADVB)
- REGIONAL HEALTH PROPERTIES, INC (RHEP)
- FLYWHEEL ADVANCED TECHNOLOGY, INC. (FWFW)
- Amesite Inc. (AMST)
- Strive, Inc. (ASST)
- Polomar Health Services, Inc. (PMHS)
- VisitIQ Corp. (VIIQ)
- Borqs Technologies, Inc. (BRQSF)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.